<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Tan R</submitter><funding>NIGMS NIH HHS</funding><pagination>852-867.e5</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC8964063</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>82(4)</volume><pubmed_abstract>Leading CRISPR-Cas technologies employ Cas9 and Cas12 enzymes that generate RNA-guided dsDNA breaks. Yet, the most abundant microbial adaptive immune systems, Type I CRISPRs, are under-exploited for eukaryotic applications. Here, we report the adoption of a minimal CRISPR-Cas3 from Neisseria lactamica (Nla) type I-C system to create targeted large deletions in the human genome. RNP delivery of its processive Cas3 nuclease and target recognition complex Cascade can confer ∼95% editing efficiency. Unexpectedly, NlaCascade assembly in bacteria requires internal translation of a hidden component Cas11 from within the cas8 gene. Furthermore, expressing a separately encoded NlaCas11 is the key to enable plasmid- and mRNA-based editing in human cells. Finally, we demonstrate that supplying cas11 is a universal strategy to systematically implement divergent I-C, I-D, and I-B CRISPR-Cas3 editors with compact sizes, distinct PAM preferences, and guide orthogonality. These findings greatly expand our ability to engineer long-range genome edits.</pubmed_abstract><journal>Molecular cell</journal><pubmed_title>Cas11 enables genome engineering in human cells with compact CRISPR-Cas3 systems.</pubmed_title><pmcid>PMC8964063</pmcid><funding_grant_id>R35 GM137883</funding_grant_id><funding_grant_id>K99 GM117268</funding_grant_id><funding_grant_id>R00 GM117268</funding_grant_id><funding_grant_id>R35 GM118174</funding_grant_id><pubmed_authors>Hou Z</pubmed_authors><pubmed_authors>Gramelspacher MJ</pubmed_authors><pubmed_authors>Zhang Y</pubmed_authors><pubmed_authors>Xiao Y</pubmed_authors><pubmed_authors>Ke A</pubmed_authors><pubmed_authors>Zhou X</pubmed_authors><pubmed_authors>Tan R</pubmed_authors><pubmed_authors>Krueger RK</pubmed_authors></additional><is_claimable>false</is_claimable><name>Cas11 enables genome engineering in human cells with compact CRISPR-Cas3 systems.</name><description>Leading CRISPR-Cas technologies employ Cas9 and Cas12 enzymes that generate RNA-guided dsDNA breaks. Yet, the most abundant microbial adaptive immune systems, Type I CRISPRs, are under-exploited for eukaryotic applications. Here, we report the adoption of a minimal CRISPR-Cas3 from Neisseria lactamica (Nla) type I-C system to create targeted large deletions in the human genome. RNP delivery of its processive Cas3 nuclease and target recognition complex Cascade can confer ∼95% editing efficiency. Unexpectedly, NlaCascade assembly in bacteria requires internal translation of a hidden component Cas11 from within the cas8 gene. Furthermore, expressing a separately encoded NlaCas11 is the key to enable plasmid- and mRNA-based editing in human cells. Finally, we demonstrate that supplying cas11 is a universal strategy to systematically implement divergent I-C, I-D, and I-B CRISPR-Cas3 editors with compact sizes, distinct PAM preferences, and guide orthogonality. These findings greatly expand our ability to engineer long-range genome edits.</description><dates><release>2022-01-01T00:00:00Z</release><publication>2022 Feb</publication><modification>2025-04-20T03:04:12.735Z</modification><creation>2025-04-20T03:04:12.735Z</creation></dates><accession>S-EPMC8964063</accession><cross_references><pubmed>35051351</pubmed><doi>10.1016/j.molcel.2021.12.032</doi></cross_references></HashMap>